NCT01399515

Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of oral valproic acid to slow the progression of visual function and/or to improve the visual function in patients with retinitis pigmentosa (RP). Enrolled subjects in valproic acid group will be treated with oral valproic acid 500mg daily for 48 weeks. Visual function and safety will be assess before and after treatment (48 weeks) between valproic acid and control groups.

Detailed description

This study is designed as a single-site, interventional, prospective, non-randomized, controlled study of 200 participants. Patients that participate in the study will be assigned to either valproic acid group or control in a 3:1 ratio.

Conditions

• Retinitis Pigmentosa
• Retinal Diseases
• Eye Diseases
• Eye Disease, Hereditary
• Retinal Degeneration

Interventions

Type	Name	Description
DRUG	Valproic Acid	One 500mg tablet by mouth daily

Timeline

• Start date: 2011-03-01
• Primary completion: 2013-08-01
• Completion: 2015-11-01
• First posted: 2011-07-21
• Last updated: 2016-04-14

Locations

1 site across 1 country: South Korea